Renee Rachelle Sinclair, CRNA MAE Nurse Anesthetist, Certified Registered Medicare: Medicare Enrolled Practice Location: 1201 W 12th Ave, Emporia, KS 66801 Phone: 620-343-6800 |
Robert Lyle Davis, CRNA Nurse Anesthetist, Certified Registered Medicare: Accepting Medicare Assignments Practice Location: 1201 West 12th Avenue, Emporia, KS 66801 Phone: 620-343-6800 |
Jeffry Alan Berry, CRNA Nurse Anesthetist, Certified Registered Medicare: Not Enrolled in Medicare Practice Location: 1201 W 12th Ave, Emporia, KS 66801 Phone: 620-343-6800 |
Jerald Dwight Campbell, CRNA Nurse Anesthetist, Certified Registered Medicare: Accepting Medicare Assignments Practice Location: 1201 W 12th Ave, Emporia, KS 66801 Phone: 620-343-6800 |
Joseph Patrick Conroy, CRNA Nurse Anesthetist, Certified Registered Medicare: Not Enrolled in Medicare Practice Location: 1201 W 12th Ave, Emporia, KS 66801 Phone: 620-343-2800 |
News Archive
Dr Laukkanen said: "Sudden cardiac death (SCD) accounts for approximately 50% of deaths from coronary heart disease. SCD typically occurs shortly after the onset of symptoms, leaving little time for effective medical interventions, and most cases occur outside hospital with few or no early warning signs. Finding ways to identify individuals at elevated risk of SCD would allow early interventions on risk factors to be implemented."
EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, announced today that it is presenting the comprehensive analysis of a recently completed Phase 2b clinical trial of EVP-6124, a novel, orally bioavailable nicotinic alpha-7 agonist, in schizophrenia at the American College of Neuropsychopharmacology 50th Anniversary Annual Meeting.
According to US health officials there are no reports that arouse new safety concerns over two children's vaccines that have been suspended in Japan following the deaths of four babies.
CytoDyn, Inc. has filed a new IND for a study to reconfirm dose ranging and to "prove the principle" with a randomized, double-blind placebo controlled study of Cytolin, the Company's first-in-class drug for treating HIV/AIDS. This comes 13 years after the first IND was issued for the drug.
Researchers at the University of California, San Diego School of Medicine have discovered that a multi-tasking protein called FoxO1 has another important but previously unknown function: It directly interacts with macrophages, promoting an inflammatory response that can lead to insulin resistance and diabetes. Contrarily, it also generates a negative feedback loop that can limit damage from excessive inflammation.
› Verified 9 days ago